1,359
Participants
Start Date
June 30, 2006
Primary Completion Date
August 31, 2006
Study Completion Date
August 31, 2006
CSL Trivalent Inactivated Influenza Vaccine - Thimerosal-free
CSL influenza vaccine-prefilled syringe presentation (thimerosal-free) 15 mcg per dose of each of the hemagglutinins of H1N1, H3N2, and B strains (total of 45 mcg of hemagglutinins). Single dose of 0.5 mL administered on study day 0.
CSL Trivalent Inactivated Influenza Vaccine with Thimerosal
CSL influenza vaccine-multiple dose vial presentation (thimerosal-containing) containing 15 mcg per dose of each of the hemagglutinins of H1N1, H3N2, and B strains (total of 45 mcg of hemagglutinins). Single dose of 0.5 mL administered on study day 0.
Placebo with Thimerosal
Phosphate buffered isotonic saline solution containing thimerosal. Single dose of 0.5 mL administered on study day 0.
University of Rochester, Rochester
University of Maryland Baltimore, Baltimore
Clinical Alliance for Research & Education - Infectious Diseases, Annandale
Duke University Medical Center, Durham
University of Iowa, Iowa City
Saint Louis University, St Louis
Baylor College of Medicine, Houston
Stanford University, Stanford
Cincinnati Children's Hospital Medical Center, Cincinnati
Vanderbilt University, Nashville
National Institute of Allergy and Infectious Diseases (NIAID)
NIH